Triple
T9807104
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | MabThera |
E238179
|
entity |
| Predicate | isMarketedAs |
P5087
|
FINISHED |
| Object |
MabThera SC for subcutaneous formulation
MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
|
E822403
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: MabThera SC for subcutaneous formulation | Statement: [MabThera, isMarketedAs, MabThera SC for subcutaneous formulation]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: MabThera SC for subcutaneous formulation Context triple: [MabThera, isMarketedAs, MabThera SC for subcutaneous formulation]
-
A.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
B.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
C.
Skyrizi
Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
-
D.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: MabThera SC for subcutaneous formulation Triple: [MabThera, isMarketedAs, MabThera SC for subcutaneous formulation]
Generated description
MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: MabThera SC for subcutaneous formulation Target entity description: MabThera SC for subcutaneous formulation is a subcutaneously administered version of the monoclonal antibody rituximab, used primarily in the treatment of certain blood cancers and autoimmune diseases.
-
A.
Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
-
B.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
C.
Skyrizi
Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
-
D.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
E.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ca84defac48190abc1148804f184c1 |
completed | March 30, 2026, 2:12 p.m. |
| NER | Named-entity recognition | batch_69cdab7cb9588190953a063cb7b9e29e |
completed | April 1, 2026, 11:34 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d1cc57119881909616d835def02fc9 |
completed | April 5, 2026, 2:43 a.m. |
| NEDg | Description generation | batch_69d1cd137b30819089356b9fbc265d17 |
completed | April 5, 2026, 2:46 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69d1cd8fcf488190bc72a99e81fb618b |
completed | April 5, 2026, 2:48 a.m. |
Created at: March 30, 2026, 8:29 p.m.